Invest1 publisher3 min readPublished
Samsung Biologics is paying for peptide capacity with new stock rather than debt, and the arithmetic inside its own 15.4 trillion won decade plan says the antibody campus, not GLP-1, still gets most of the money.
The Investor · Invest desk
Compiled by The InvestorSomething wrong?How this is made
Set the peptide purchase inside the decade it belongs to and the proportions do the arguing. Roughly 7 trillion won is earmarked for a third Bio Campus, about 1.9 trillion won for Plant No. 6 and about 1.8 trillion won for Plant No. 7 [7], which is 10.7 trillion won of brick and steel, or 69.5% of the 15.4 trillion won total [6]. PolyPeptide, at 2.7062 trillion won [2], is 17.6% [5]. The four named lines together come to 13.4 trillion won, leaving about 2 trillion won for the US facilities and the new ADC and drug-product equipment [4]. Peptides buy a position; the antibody footprint takes the capital.
On the terms themselves, 2.27 million new shares for 3 trillion won implies about 1.32 million won a share [2], and once the 294.8 billion won for Songdo is set aside, 90.2% of the raise is simply the purchase price [1]. The hole being plugged is narrower than the raise suggests: 2.2 trillion won of cash at the half year against a 2.7062 trillion won price is a 506 billion won gap [3], close to the roughly 500 billion won year-end shortfall the company itself describes [4]. The offering, then, is what lets Samsung Biologics avoid choosing between PolyPeptide and everything already on the schedule.
What the material does not contain is a revenue or earnings figure for PolyPeptide, which leaves 2.7062 trillion won as a price with no published multiple attached, and Goldman Sachs' description of the acquisition as an important milestone in the fast-growing peptide CDMO market [10] is a statement about position rather than about return. The assets are concrete enough: production plants in Europe, the United States and India, plus the prospect of selling peptide work to customers already buying antibody manufacturing [8].
My read, and cross-selling is where I would most want to be wrong, is that the equity route is the cheap half of this deal, because dilution of about 4.9% [3] is a cost incurred once at a price anyone can see, while the case for 2.7062 trillion won rests on antibody customers choosing the same vendor for peptides [8], a benefit the company expects rather than one it has shown. The versions that diverge from here are not hard to name. Load those European, American and Indian lines with commercial volume and the purchase looks like capacity bought ahead of demand; leave them under-loaded and 2.7062 trillion won bought geography and a customer list; fund the remainder of the 15.4 trillion won out of the stable operating cash inflows the CFO says he expects, without returning to holders [12], and the 4.9% is the entire entry fee for peptides, which is the version worth underwriting.
Ranked by verification strength, evidence, and original report placement.
Samsung Biologics recently decided on a 3 trillion won rights offering, according to industry sources cited on the 6th.
Of the funds raised, 2.7062 trillion won will go toward the PolyPeptide Group acquisition and the remaining 294.8 billion won toward expansion of the second Bio Campus in Songdo and other projects.
Samsung Biologics will issue 2.27 million new shares, an increase of about 4.9%.
Samsung Biologics said it held about 2.2 trillion won in cash and cash equivalents as of the first half of this year, but that executing planned investments as scheduled would leave it about 500 billion won short by year-end.
Samsung Biologics said funding the acquisition entirely through borrowing could push its debt-to-equity ratio to the high 80% range.
Samsung Biologics plans to invest a total of 15.4 trillion won through 2034, including the PolyPeptide Group acquisition, Plants No. 6 and No. 7, a third Bio Campus and expansion of US manufacturing facilities.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Issuer's figures, one outlet
Almost every number traces to Samsung Biologics itself, most of it delivered at a briefing held to explain the offering: the cash balance, the year-end shortfall, the debt-to-equity alternative, the 15.4 trillion won plan and its line items. The decision to raise is attributed to industry sources rather than to a filing or a named officer. What raises the floor is internal consistency, since the use-of-proceeds figures, the share count and the plant costs all reconcile against the totals, so the disclosed arithmetic can be checked even though the source of it cannot be corroborated.
Funding secured before volumes appear
What can be dated so far is a funding decision and a briefing about it. There is no closing date for the PolyPeptide purchase, no regulatory clearance, no customer, and no peptide volume figure on either side of the deal. The measures the reporting itself nominates, GLP-1 tonnage and Phase 3 assets reaching commercial production, can only be read later, so nothing in the supplied material speaks to uptake.
Antibody-heavy budget behind a peptide headline
The story is told as an entry into GLP-1 peptides that secures a new growth axis, and the company's own allocation puts 10.7 trillion won, about seven-tenths of the decade plan, into Plants No. 6 and No. 7 and a third Bio Campus, against 2.7062 trillion won for PolyPeptide. The raise being celebrated funds 19.5% of the programme it is presented as enabling. Analyst welcome is asserted broadly and carried by a single named bank.
Numbers built for a sell
These figures were assembled to persuade shareholders to accept 4.9% dilution, and the reporting carries that purpose largely intact. The CFO's rationale comes from the briefing convened for exactly that job; the sceptical passage cites analysts without naming one; the approving passage names Goldman Sachs without saying whether the bank has any role in the offering. The company also has a straightforward reason to publicise the high-80% debt-to-equity figure, since it makes the equity route look like restraint.
Deal arithmetic checks out, though the outcome stays uncertain
The checkable parts hold: proceeds against share count, line items against the 15.4 trillion won total, acquisition price against the half-year cash balance. So the shape of the deal and the size of the dilution are dependable. Everything that determines whether it was worth doing, PolyPeptide's earnings contribution and cross-selling into the antibody book, is a projection made by the party asking for the money, and no second account exists to test it.
product
Nebius funds $4.5bn of AI capacity on terms that pay lenders mostly in stock2 publishers
invest
Nvidia put a number on the bubble argument: 70% growth, and it can now be scored2 publishers
build
SMIC's first $3 billion quarter comes with a wafer price increase attached1 publisher
product
Quintessent raises $40M to put quantum dots in the laser slot of AI fabrics1 publisher
Publishers with included, body-backed reporting in this cluster.
1 article · September 6, 2026